characterized by CD11c and T-bet expression associated with clonal expansion and 23 differentiation toward effector function. Vaccination elicited an antibody clone which 24 rapidly acquired broad high-affinity hemagglutinin binding during affinity maturation. 25 Unexpectedly, many antibody clones elicited by vaccination do not bind vaccine, 26
demonstrating non-specific activation of bystander antibodies by influenza vaccination. 27
These results offer insight into how molecular recognition, transcriptional programs, and 28 clonal proliferation are coordinated in the human B cell repertoire during memory recall. 29 30
Main Text: 31
Antibody memory is a hallmark of adaptive immunity and confers life-saving 32 protection against many pathogens. During initial encounter with a pathogen, clonal 33 selection and affinity maturation focus the antibody repertoire onto variants that bind 34 specifically to pathogen-derived antigens with high affinity, and these antibodies are 35 preserved in memory B cells. In subsequent encounters, memory B cells are rapidly 36 activated, leading to clonal expansion and differentiation to antibody-secreting cells. This 37 robust immune response can prevent reinfection or reduce severity of disease. 38
Although a protective memory response requires coordination of antigen 39 recognition, gene expression, and clonal expansion, studies linking these facets of the 40 response have been lacking. Specifically, deep sequencing-based measurements of the 41 population dynamics and clonal structure of the B cell repertoire have shown that 42 vaccination typically induces rapid expansion of a small set of B cell clones within 7 days 43
(1-3). However, the transcriptional programs of these expanded clones and the antigen 44 specificity of their antibodies have not been characterized. 45
Analogously, antigen-resolved measurements, such as serum binding assays and 46 antigen-specific cell sorting, have demonstrated that antigen-specific serum antibody (4, 47 5), memory B cells (6), and antibody-secreting cells (7) become more abundant after 48 vaccination. However, these approaches have not been able to resolve clonal 49 relationships among antigen-specific cells, the population dynamics of these clones, or 50 their gene expression programs. 51
Finally, bulk transcriptome measurements have detected transient expression 52
signatures associated with memory recall after vaccination in blood (8, 9) and B cells 53 (10), but it is not known how these transcriptional programs are related to clonal 54 dynamics and antigen specificity within the B cell repertoire. Thus, an integrated portrait 55 of how the memory response unfolds with cellular and molecular detail at the scale of the 56 entire organism's antibody repertoire remains lacking, despite its importance for 57 protective immunity and vaccine design. 58
To address these questions, we developed an integrative approach that combines 59 information from single-cell transcriptomics, longitudinal antibody repertoire sequencing, 60
and antibody binding measurements, and applied it to study the human antibody response 61 to influenza vaccination. We tracked the population dynamics of B cell clones in a time 62 course after vaccination and profiled transcriptomes of single B cells within those clones, 63
revealing an activated memory B cell state associated with vaccine-elicited clonal 64 expansion. We then assessed the relationship between clonal expansion and antigen 65 specificity by expressing native human antibodies isolated from single B cells and 66 characterizing their binding properties. 67 68
Integrating single B cell phenotypes with clonal population dynamics after 69 vaccination 70 We studied the antibody repertoire response of one healthy young adult (age 18) 71
to seasonal influenza vaccination in 2012. Deep multimodal study of a single individual's 72 vaccine response enabled us to extensively investigate the relationships between global 73 repertoire structure and molecular function using a diverse suite of experimental 74 techniques. To measure the population dynamics of the vaccine response, we sequenced 75 the peripheral blood antibody repertoire (Rep-seq) at the time of vaccination and 1, 4, 7, 76 9, and 11 days afterward (D0, D1, D4, D7, D9, and D11), as well as 3 and 5 days before 77 vaccination (D-3 and D-5) ( Figure 1A and Figure 1B ), as we previously reported (3). We 78 detected ~625,000 unique antibody heavy chain sequences belonging to ~55,000 clonal 79 lineages. Vaccination induced rapid recall of 16 vaccine-responsive clones, which were 80 defined as those having >50-fold expansion in unique sequences detected between D0 81 and D7. These clones bear the hallmarks of memory B cells, including extensive somatic 82 mutation, class-switched isotypes, and population genetic signatures of positive selection 83
(3). 84 We also sequenced antibody heavy and light chain transcripts in single B cells 85 purified from peripheral blood samples of the same subject at D7 and D9, which 86
correspond to the peak of the memory response ( Figure 1B ). After quality filtering and 87 computational removal of doublets, we obtained 94,259 single B cells having exactly one 88
productive heavy chain and one productive light chain transcript ( Figure S1A and Figure 89 S1B). We detected cells producing antibodies of every class, and the majority of cells 90 produced IgM antibodies, as expected from pan-B cell purification, which includes naïve 91 B cells ( Figure S1C ). 92
To connect single-cell phenotypes with clonal population dynamics, we mapped 93 these single B cells to clones detected by Rep-seq using an established approach for 94 identifying clonal lineages via single-linkage clustering ( Figure S1D ) (11, 12) . Clones 95
were identified in the Rep-seq repertoire for 8% of cells, with the nearest heavy chain 96 complementarity determining region (HCDR3) exhibiting high identity (97% ± 3%, mean 97 ± s.d.) for these matches ( Figure S1E ). Matches were strongly enriched for class-98 switched isotypes and depleted for IgD, as expected for memory B cells ( Figure S1F ). 99
The majority of cells did not match a clone in Rep-seq data because most cells are naïve 100 B cells, as confirmed by transcriptome profiling below. Additionally, the resampling 101 probability of low abundance memory B cell clones across replicate samples is low (1). 102
Nevertheless, for clones detected in both measurements, quantification of clone size was 103 highly consistent across the two methods ( Figure 1C ; Spearman's rho = 0.57, P < 10 -91 ). 104
Based on the Rep-seq measurement of clonal population dynamics, we identified 105 five vaccine-responsive clones that both expanded dramatically after vaccination (>50 106 fold-change from D0 to D7) and contained sequenced single cells. This included the two 107 globally most abundant clones at the peak of recall at D7, and each clone comprised 108 >0.1% of the repertoire at D7 (range 0.1 -8%) ( Figure 1D ). Antibodies in these vaccine-109
responsive clones were mostly IgG (94%) and had extensive somatic hypermutation 110 (mutation density 3.8% ± 1.4%, mean ± s.d.). These results establish that the combination 111 of longitudinal Rep-seq and single-cell sequencing captures a rich portrait of B cell 112 population dynamics at the scale of the whole organism, and links single-cell phenotypes 113 such as paired heavy-light chain antibody sequences with clonal population dynamics. 114
Because single-cell sequencing preserves the native pairing between heavy and 115 light chain sequences, we were able to assess the fidelity of the widely-used strategy of 116 clone identification based on heavy chain sequence alone by using the light chain as an 117 independent marker of clonal identity. Light chain genes were highly concordant within 118 the vast majority of clones, as evidenced by the majority light chain gene representing a 119 very high proportion of cells within each clone ( Figure S1G ; median = 100%, mean ± s.d. 120 = 90% ± 18% for light chain constant region genes; similar results were found for light 121 chain V and J genes). We observed that a minority of clones (16%) had substantial 122 impurity based on the presence of cells containing a plurality of different light chain 123 genes. We determined that these impure lineages were strongly enriched for short 124 HCDR3 sequences ( Figure S1H ; P = 3.8 × 10 -91 , Mann-Whitney U test; median HCDR3 125 length 14 AA in impure lineages, 16 AA in pure lineages) and usage of the IGHJ4 gene, 126
which contributes a longer templated insert to the HCDR3 and thus tends to reduce 127 sequence diversity ( Figure S1H ; P = 5.1 × 10 -225 , Fisher's exact test; 64% IGHJ4 usage in 128 impure lineages, 28% in pure lineages). We conclude that the fidelity of clone 129 identification based on clustering of heavy chain sequences is high for most clones. Clone 130 assignment errors predominantly arise from low diversity compartments of the repertoire, 131
and assignment can be improved by using light chain sequences when pairing 132 information is available. 133 134
Transcriptional program of vaccine-induced memory B cell activation 135
We performed single-cell transcriptome profiling on 35,631 cells, comprising a  136 subset of the cells for which we sequenced antibody transcripts ( Figure 2A ). We detected 137 a median of 2,015 UMIs and 766 genes per cell ( Figure S2A ), as typical for microfluidic 138 droplet-based single-cell sequencing (13). Similar transcriptional profiles were obtained 139 across 4 technical replicates ( Figure S2B ) and these data were pooled for analysis. Using 140 t-SNE visualization and DBSCAN clustering, we identified distinct immune cell types, 141
which we manually annotated based on established type-specific genes ( Figure 2B ). 142
Three clusters corresponded to CD4+ and CD8+ T cells and macrophages, which 143 displayed specific expression of markers such as CD3E for T cells and LYS for 144 macrophages ( Figure S2D ) and lacked antibody expression ( Figure 2C ). These cell types 145 were present at low abundance due to the imperfect purity of B cell isolation and were 146 not analyzed further. B cells formed two distinct clusters, which we annotated as memory 147 B cells and naive B cells based on established markers and antibody isotype ( Figure 2B ). 148
Memory B cells expressed CD27 ( Figure S2E ) and made predominantly class-switched 149 antibodies ( Figure 2C and Figure S2C ). Naive B cells expressed TCL1A ( Figure S2E ) and 150 made exclusively IgM and IgD antibodies ( Figure 2C and Figure S2C ). In total, we 151 analyzed 16,653 memory and 18,953 naive B cells. 152
To address how clonal population dynamics are related to transcriptome state, we 153 mapped the single B cell transcriptomes to the clones identified using Rep-seq based on 154 heavy chain sequence, as described above. Matches to clonal lineages were obtained 155 almost exclusively for memory B cells as expected ( Figure 2D ). Remarkably, we found 156 that cells belonging to vaccine-responsive clones had a distinct transcriptional profile 157 characteristic of a small neighborhood within the memory B cell cluster ( Figure 2D ). 158
Cells in this neighborhood expressed established genes related to B cell activation, 159
including the activation marker CD86 and the somatic hypermutation gene AICDA, also 160 known as AID ( Figure 2E , Figure 2F , and Figure S2E ). Thus we annotated cells in this 161 neighborhood as activated memory B cells, comprising 421 cells in total. 162
To define the transcriptional programs of B cell states, we identified genes 163 exhibiting differential expression across naive, memory, and activated memory B cells. 164 We found 755 differentially expressed genes between naive and memory B cells (FDR = 165 0.1%, Mann-Whitney U test with Benjamini-Hochberg correction), including established 166 markers such as CD27 and IGHD ( Figure 2E ). About half of these genes were 167 upregulated in naive B cells, while the other half were upregulated in memory B cells 168 ( Figure S2G ). By contrast, we found 172 differentially expressed genes between memory 169 and activated memory B cells, all of which were upregulated in activated memory B cells 170 ( Figure S2G ). Dominant upregulation of genes in the activated memory state was 171 consistently observed across a range of significance thresholds defining differential 172 expression ( Figure S2G ). We also detected more genes (median 1,786) and more UMIs 173 (median 5,517) in activated memory B cells than memory B cells ( Figure S2F ; median 174 gene count in memory B cells = 849, UMI count = 2,406), possibly reflecting greater 175 mRNA content due to elevated transcription. Together, these results suggest that the 176 transcriptional program of memory B cell activation predominantly involves activation 177 rather than deactivation of gene expression. 178
To characterize the activated memory B cell state, we first sought to identify 179 transcription factors (TFs), which may be central regulators of the program of activation. 180
We identified 6 TFs specifically expressed in activated memory B cells ( Figure 2G ). 181
These TFs include T-bet, also known as TBX21 ( Figure S2E ), which is required for IgG2a 182 class switching (14) and clearing chronic viral infections (15), and Zbtb32, which 183 modulates the duration of memory B cell recall responses in mice (16). 184
Several cytokine receptors are downregulated in activated memory B cells ( Figure  185 2H). IL4R and IL21R are highly expressed in naive B cells, but downregulated in memory 186 and activated memory B cells ( Figure 2H and Figure S2E ), suggesting that naive B cells 187 are more responsive than memory or activated memory B cells to IL4 and IL21, which 188 regulate class switching to IgG4 or IgE (17), and IgG1 or IgG3 (18), respectively. The 189 chemokine receptor CXCR4, which controls entry to anatomical locations of B cell 190 maturation, such as lymph nodes and Peyer's patches (19), is also progressively 191 downregulated from naive to memory and activated memory B cells ( Figure 2H ). 192
Other genes related to humoral activation are upregulated in activated memory B 193 cells. The chemokine receptor CXCR3, which is required for cell migration to sites of 194
inflammation (20), is specifically expressed in activated memory B cells ( Figure 2H and 195 Figure S2E ). Interestingly, CD11c, also known as ITGAX, is specifically expressed in 196 activated memory B cells ( Figure 2H ), suggesting that this state overlaps with the 197 recently described age/autoimmune-associated B cells (21, 22) . Finally, EBI3, which is 198 known to be expressed in germinal center B cells (23), is found exclusively in activated 199 memory B cells ( Figure 2F ). Complete lists of differentially expressed genes across 200 naive, memory, and activated memory B cells are shown in Table S1 and Table S2 . 201
Together, these results define a transcriptional program of memory B cell activation 202 associated with vaccine-induced clonal expansion, which bears hallmarks of an effector B 203 cell response. 204 205
Many vaccine-responsive antibodies do not bind vaccine 206
To study how clone dynamics and antigen specificity are related, we expressed 207 and functionally characterized 21 antibodies obtained from single B cells within 5 208 vaccine-responsive clones ( Figure S3A ). We first measured binding of these antibodies to 209 the vaccine (trivalent influenza vaccine from the 2011-2012 flu season) by ELISA. 210
Surprisingly, only 57% of the vaccine-responsive antibodies (12 of 21) and 40% of 211 vaccine-responsive antibody clones (2 of 5) exhibited binding to vaccine ( Figure 3 and 212 Figure S3B ). For the non-vaccine-binding antibodies, we further screened for binding by 213
ELISA against a panel of purified influenza proteins, including hemagglutinins, 214 neuraminidases, nucleoprotein, matrix protein, and non-structural proteins, but found no 215 binding ( Figure S3C ). Notably, despite not binding vaccine or influenza proteins, these 216 three clones expanded dramatically after vaccination (>62-fold) and were highly 217 abundant at D7, including one clone which was the second most globally abundant clone, 218 representing 6.7% of the repertoire at D7. These results indicate that many vaccine-219 responsive antibodies do not bind vaccine or purified components of the vaccine. This 220 suggests that vaccination induced activation of some antibody clones in an antigen-221 independent manner. We found no binding of these non-vaccine-binding antibodies to a 222 panel of common viral and bacterial antigens, such as herpes simplex, measles, and 223 varicella zoster virus ( Figure S3C ), and we were unable to determine the specificities of 224 these antibodies.
226
A
broadly binding high-affinity anti-influenza antibody clone elicited by vaccination 227
To determine the specificity of the vaccine-binding antibodies, we screened them 228 for binding by ELISA against purified influenza proteins, including the major antigenic 229 determinants of influenza virus, hemagglutinin (HA) and neuraminidase (NA). One 230 vaccine-responsive clone, which we refer to as L3, displayed strong binding to diverse 231 HA proteins, including the influenza A variants contained in the vaccine, H1 232 A/California/7/2009 and H3 A/Perth/16/2009, as well as H5 and H9 variants ( Figure 4A ). 233
These antibodies had similar binding strength and breadth as established broadly 234 neutralizing antibodies MEDI8852 (24) and CR9114 (25) ( Figure 4A ). L3 antibodies use 235 the IGHV3-34 and IGHJ4 genes, have a 19 AA HCDR3, and are heavily mutated (28 ± 5 236 mutations from inferred germline heavy chain, mean ± s.d.) ( Figure S3A ). 237
We measured the binding affinity of L3 antibodies to diverse H1 and H3 variants 238 using biolayer interferometry. Most L3 antibodies bound with sub-nanomolar affinity to 239 both H1 and H3, which are highly divergent HA variants drawn from the two major 240 groups of influenza A virus and share only 44% amino acid identity ( Figure 4C and 241 Figure S4C ; equilibrium binding constants [K D ] from 18 nM to 50 pM). Thus, L3 broadly 242 binds diverse hemagglutinin variants with high affinity. A second vaccine-binding clone, 243
which we call L1, displayed strong but narrow binding specificity to HA B ( Figure S3C ) 244 and we did not analyze this clone further. 245 246
Evolution of a broadly binding anti-influenza antibody clone 247
To shed light on the evolutionary trajectories leading to broad high-affinity anti-248 influenza binding, we reconstructed the clonal evolution of L3 ( Figure 4B ). Using 249 maximum-likelihood phylogenetic models, we reconstructed the ancestral sequences of 250 the unmutated germline precursor and four intermediate ancestors ( Figure S4A and 251 Figure S4B ), then expressed these antibodies and measured their binding affinities to 252 diverse HAs. While the germline precursor bound weakly to H1 and H3 (K D > 1 uM) 253
( Figure S4E ), the first intermediate ancestor A1 bound to both H1 and H3 with 254 nanomolar affinity (K D = 1.5 nM and 2 nM, respectively) ( Figure 4C ), despite having 255 acquired only 11 amino acid substitutions (6 in the heavy chain and 5 in the light chain) 256
( Figure S4A ). 257
To dissect the contributions of heavy and light chain mutations to binding affinity, 258
we engineered variants of the high-affinity L3N6 antibody in which the heavy and light 259 chain sequences were separately reverted to the respective germline precursor sequence 260
( Figure S4A and Figure S4B ). We found that germline reversion of the heavy chain 261 greatly reduced binding affinity to both H1 and H3 (K D > 1 uM) ( Figure 4C and Figure  262 S4E). In contrast, germline reversion of the light chain minimally affected binding to H1 263 and H3 (K D = 27 nM and 10 nM, respectively) ( Figure 4C and Figure S4E ). To further 264 test the contribution of light chain mutations, we created a variant of L3N6 in which the 265 light chain was swapped for a different IGK sequence originating from a distinct clonal 266 lineage having a different LCDR3 ( Figure S4B ). This alteration of the light chain also 267 minimally affected binding to H1 and H3 (K D = 8 nM and 94 nM, respectively) ( Figure  268 4C and Figure S4E ). These findings show that heavy chain mutations were 269 predominantly responsible for affinity maturation, indicating that broad nanomolar-270 affinity binding was achieved via ≤6 amino acid substitutions in the heavy chain. 271 L3 antibodies therefore rapidly evolved broad high-affinity binding to diverse HA 272 variants through a small number of somatic mutations. Affinity improvements were 273 predominantly driven by decreasing the dissociation rate, which varied ~10,000-fold 274 across the clone, rather than increasing the association rate, which varied only ~10-fold 275 ( Figure S4D ). We found evidence for an affinity ceiling: acquisition of mutations beyond 276 the intermediate ancestor A1 did not substantially affect affinity and there was no trend 277 toward enhanced affinity with additional mutations (across the range of 18 -38 278 mutations from the inferred germline IGH sequence) ( Figure 4D ; Spearman's rho = 0.25, 279 P = 0.37). Instead, L3 antibody affinity evidently drifted neutrally after acquisition of 280 high-affinity binding. 281
To determine how L3 antibodies bind HA, we performed cross-competition 282 binding experiments using biolayer interferometry. We competed L3N1 and L3N6 283 against a panel of broadly binding antibodies consisting of stem-binding antibodies 284 CR9114 (25) and MEDI8852 (24), receptor-binding site antibodies CH65 (26) and 285
H2897 (27), and lateral patch antibody 6649 (28). We found that L3N1 and L3N6 did not 286 compete with any of these antibodies ( Figure S5 ). This result indicates that the epitopes 287 recognized by L3 antibodies do not overlap with any antibodies in this panel, suggesting 288
that L3 achieves broad specificity by a distinct structural mechanism. Furthermore, the 289 L3 epitope may be conserved across HA variants belonging to groups 1 and 2. 290
It has been proposed that the antibody memory response is biased towards 291 antigens seen early in an individual's life, and this priming influences subsequent 292
responses (29). To test this hypothesis using L3, we compared binding affinity to H1 293 variants that circulated during the subject's childhood and adulthood. We found that 294 extant antibodies of the L3 clone nearly all bound with higher affinity to the childhood 295 strain (H1 New Caledonia/20/1999) than the adult strain (H1 California/07/2009) ( Figure  296 4D). This indicates that the affinity of a broad binding anti-HA antibody clone is biased 297 towards antigenic variants associated with childhood exposure, supporting the hypothesis 298 that affinity maturation most efficiently focuses the antibody repertoire on antigens 299 encountered in early life, leaving an lasting imprint on subsequent responses. 300 301
Discussion 302 Mobilization of an effective antibody memory response requires coordination 303 across scales, from antibody-antigen recognition and transcriptional activation in single 304 cells to clonal population dynamics that globally remodel an organism's antibody 305
repertoire. This complex, multi-scale nature of the immune system creates challenges for 306 understanding its function. To address these challenges, we have developed an 307 experimental approach that integrates single B cell sequencing with longitudinal antibody 308 repertoire sequencing and biophysical measurements of antibody function. Our results 309
show that this strategy offers a unified portrait of the molecular and cellular features of 310 the memory B cell response to vaccination, giving insights into mechanisms of immune 311 memory. 312
Much recent interest has focused on a functionally specialized B cell subset 313 marked by CD11c and T-bet expression named "Age/autoimmune Associated B cells" 314 (ABCs). B cells with these features are associated with viral infections, autoimmunity, 315
and aging in mouse and human (21, 22, (30) (31) (32) , but to our knowledge the phenotype has 316 not been described as a transcriptional state with single-cell resolution. Using single-cell 317 transcriptomics and longitudinal clone tracking, we have defined an activated memory B 318 cell state, which displays hallmarks of an effector B cell response and shares many 319 features with ABCs, including high expression of CD11c (21, 22) , T-bet (31), FCRL4, 320
and CXCR3 (30). Several genes that define this activated memory B cell state are directly 321 involved in germinal center migration (EBI3) (23), somatic hypermutation (AICDA) (33), 322
and class switching (AICDA and Tbx21) (14, 33), suggesting that these cells are poised 323 for secondary affinity maturation. Our results indicate that these CD11c+ T-bet+ B cells 324 are associated with vaccine-elicited clonal expansion in a healthy young adult human. 325
These findings support the view that CD11c+ T-bet+ B cells are essential to health, but 326 aberrant regulation of them can lead to autoimmunity. Defining their transcriptional 327 program opens avenues to understanding their origins, function, and regulation, which 328 may in turn reveal therapeutic targets in both pathogen immunity and autoimmunity. 329
Unexpectedly, several antibody clones elicited by vaccination did not bind 330
vaccine. Formally, we cannot exclude that the lack of binding between recombinant 331 vaccine-responsive antibodies and the vaccine in vitro is due to conformational changes 332 occurring under physiological conditions. Notwithstanding this alternative explanation, 333
our results suggest that bystander activation of memory B cells bearing non-vaccine 334 specificities is common after influenza vaccination. Polyclonal activation of memory B 335 cells bearing non-vaccine specificities after vaccination has previously been described at 336 the level of serum antibody (34) and antibody-secreting cells (7). Similarly, infection 337
with both measles and varicella induces non-specific B cell activation (35). Our results 338
show that many, perhaps even the majority of, memory B cells elicited by influenza 339 vaccination produce antibodies that do not bind the vaccine, revealing an unanticipated 340 extent of this phenomenon. This extent comports with some previous studies based on 341 single-cell cloning of antibody-secreting cells (7), but may have been underestimated in 342 other studies that tested binding against limited panels of antigens (34, 36). Non-specific 343 polyclonal activation has been proposed as a mechanism for maintenance of long-term 344 immune memory, enabling memory cell proliferation in the absence of antigen encounter 345 (37). We were not able to identify antigens for the non-vaccine-binding antibodies by 346 screening against a panel of common viral and bacterial antigens; conclusive 347 identification of non-vaccine specificities will require high-throughput screening 348 methods. Nevertheless, our integrated strategy of single-cell and Rep-seq offers a direct 349 route to characterization of these non-vaccine-specific yet vaccine-elicited antibodies. 350
Our results also indicate that bystander activation is confined to a small number of clones 351 by an unknown mechanism, perhaps related to the presence of activated T cells (38) (39) (40) . 352 We discovered a broadly binding anti-hemagglutinin antibody clone in which 353 fewer than six somatic mutations in the heavy chain alone was sufficient to confer broad 354 high-affinity binding, offering a striking example of rapid affinity maturation. TCL1A  TCL1B  GCNT1  IL4R  PCDH9  IL21R  YBX3  SATB1  SEMA4A  HOXB2  CXCR4  CD27  CD70  ZBTB32  AIM2  CLECL1  KLK1  CXCR3  EBI3  TCF7  TFEC  KLF10  DHRS9  AICDA  KREMEN2  TBX21  FCRL4  STAC3  ITGAX  POU4F1  FCER1G  CD86  ZEB2 Evolutionary history of L3 depicted as a maximum-likelihood phylogeny based on heavy 543 chain sequence. Markers indicate antibodies detected by single-cell sequencing (N1-7) or 544
repertoire sequencing (R1-7), or reconstructed ancestral sequences (germline and A1-4). Study subject gave informed consent and protocols were approved by the Stanford 567
(C) Equilibrium constants (K D ) of binding between L3 antibody variants and H1 546
Institutional Review Board. Subject was a female human aged 18 who was recruited in 568 2012. The subject was apparently healthy and showed no signs of disease. 569 570
Sample collection 571
As previously described (3), blood was drawn by venipuncture, then peripheral blood 572 mononuclear cells (PBMCs) were isolated using a Ficoll gradient and frozen in 10% 573
(vol/vol) DMSO and 40% fetal bovine serum (FBS) according to Stanford Human 574
Immune Monitoring Center protocol. Subject was vaccinated with the 2011-2012 575 seasonal trivalent inactivated influenza vaccine. Blood was collected 3 and 5 days before 576 vaccination (D-3 and D-5); immediately before vaccination (D0); and 1, 4, 7, 9, and 11 577 days afterwards (D1, D4, D7, D9, D11). 578 579
Antibody repertoire sequencing 580
Antibody repertoire sequencing was previously performed on samples from all timepoints 581 and preprocessed data was downloaded (3). Briefly, PBMCs were thawed and RNA was 582 extracted. This RNA was reverse transcribed using immunoglobulin heavy chain constant 583 region-specific primers and cDNA was amplified by PCR. UMIs were incorporated 584 during reverse transcription and PCR. These libraries were sequenced using the Illumina 585
HiSeq 2500 and MiSeq platforms using paired-end 101 or 300 bp reads, respectively. 586
Consensus-based error correction was performed using UMIs. Sequences were annotated 587 with V and J germline gene usage using IgBlast (43) and isotype using BLASTN (44). 588
Clonal lineages were identified based on V and J gene usage, HCDR3 length, and 589 HCDR3 sequence composition. Dynamics of clones were determined by comparing 590 fractional abundance across study timepoints. As in our previous study (3), vaccine-591 responsive clones were identified as those having >50-fold expansion from D0 to D7 and 592 composing >0.1% of the repertoire at D7. 593 594
Single-cell isolation and sequencing 595
PBMCs from D7 and D9, which correspond to the peak of the B cell memory recall 596 response, were thawed. B cells were magnetically enriched using the B Cell Isolation Kit 597 II (Miltenyi). Single cells were encapsulated in droplets using 16 lanes of the Chromium 598 device (10X Genomics) with target loading of 14,000 cells per lane. Reverse transcription 599 and cDNA amplification were performed using the Single Cell V(D)J kit (10X 600 Genomics). In 12 lanes, direct enrichment of VDJ was performed. In the remaining 4 601 lanes, VDJ and gene expression measurement was performed; these 4 lanes were 602 considered technical replicates. All steps were done according to manufacturer's 603 instructions, except with additional cycles of polymerase chain reaction (PCR) (19 total 604 cycles for direct enrichment of VDJ; 22 total cycles for VDJ and gene expression). 50 ng 605 of cDNA was used as input for library preparation. Libraries were sequenced using the 606
Illumina NextSeq 500 platform with paired-end reads for VDJ of 150 bp each and for 607 gene expression of 26 bp and 98 bp. 608 609
Preprocessing of single-cell sequence data 610
Sequences were preprocessed to map reads to the human reference genome (GRCh38) 611 using STAR 2.5.1b (45), count molecules aligning to each gene, and assemble antibody 612 heavy and light chain transcripts within cellranger 2.1.0. To distinguish bona fide single 613 cells from multiplets, we examined the number of productive heavy and light chain 614 contigs assembled for each cell barcode. Single B cells were identified by the presence of 615 a single productive heavy chain and a single productive light chain, yielding a total of 616 94,259 single B cells for analysis. All other cells were excluded from further analysis. 617 618
Mapping single B cells into clones 619
Single B cells were mapped to clones using a custom algorithm similar to that used for 620 identification of clones previously (3, 11) . Sequences detected by repertoire sequencing 621 (n = 625,750) were annotated for V and J gene usage, HCDR3 length, and HCDR3 622 sequence and formed the database of subject sequences. The heavy chain variable region 623 sequence from each single B cell was used as a query to search this database. For each 624 query, the set of subjects sharing the query's V and J genes and CDR3 length was 625 identified. Within this set, the identity between the query and subject sequences within 626 the HCDR3 and outside the HCDR3 were calculated based on Hamming distance, and 627 hits were defined as having >90% nucleotide identity in both regions. Previous studies 628 have demonstrated that this cutoff of sequence identity enables identification of clonally 629 related sequences with high sensitivity and specificity (11, 12) . This yielded 8,377 single 630 B cells that had matching clones detected by repertoire sequencing. 631
Fidelity of clonal clustering was assessed using the light chain as an independent 632 marker of clonal identity. In clones having multiple B cells detected by single-cell 633 sequencing, the percentage of cells possessing the dominant light chain was determined. 634
Impure clones were identified as those having <80% of cells within the clone sharing the 635 dominant light chain. All of the vaccine-responsive clones were pure. 636 637
Analysis of gene expression in single cells 638
Gene expression profiles were log-transformed and normalized to counts per million 639 molecules. Dimensionality reduction using principal components analysis (PCA) 640 retaining the top 10 principal components followed by t-distributed Stochastic Neighbor 641
Embedding (tSNE; perplexity = 30, theta = 0.5, max_iter = 1,000) (46) were performed 642 using cellranger 2.1.0. Clusters were identified using Density-Based Spatial Clustering of 643
Applications with Noise (DBSCAN; eps = 0.66, min_samples = 10) (47) and annotated 644 based on expression of established marker genes for each cell type. Differentially 645 expressed genes were identified using the negative binomial exact test adjusted for 646 multiple testing using the Benjamini-Hochberg procedure as implemented in Loupe 2.0.0 647 (10X Genomics). For visualization of differential expression, the Z-score of expression of 648 each group of cells was computed in comparison with the mean and standard deviation of 649 expression in all other cells. Data visualization and analysis were performed using 650
Scanpy (48) within JupyterLab (49). 651 652
Reconstructing the evolutionary history of antibody clone L3 653
Evolutionary analysis was conducted sequences in clone L3 obtained by repertoire 654 sequencing using paired-end 300 bp reads (n = 125) and single-cell sequencing (n = 7). 655
Sequences were initially aligned in an ungapped manner using the start and end positions 656 of the HCDR3 as anchor points. This alignment was refined using MUSCLE 3.8.31 with 657 "-refine -maxiters 1 -diags -gapopen -5000" (50), then trimmed to remove positions 658 which were only covered by single-cell sequencing contigs (which are substantially 659 longer than repertoire sequencing assemblies). We added an inferred germline sequence 660 consisting of the reference heavy chain V and J genes and the consensus of the alignment 661
for the untemplated regions of the HCDR3. Phylogenetic reconstruction was performed 662
using FastTree 2.1.7 with "-nt -gtr" (51). We concatenated light chain sequences to this 663 alignment, then performed reconstruction by maximum-likelihood assuming equal rates 664 for all mutations. 665
To assess the contribution of heavy and light chain mutations to binding, we 666 engineered variants of the high-affinity antibody L3N6 by substituting either the inferred 667 germline heavy (germline IGH) or light (germline IGK) chain sequence. We also 668 substituted the light chain with a randomly chosen sequence from a different clonal 669 lineage that used the same VK gene, but had a distinct LCDR3 (IGK swap). For cloning 670 and expression of antibodies derived from repertoire sequencing (R1-7), we used the 671 light chain sequence originating from the single cell nearest the selected antibody, using 672 the metric of heavy chain nucleotide sequence identity. These antibodies were chosen to 673 span a wide range of somatic mutation levels. 674 675
Recombinant antibody expression 676
Recombinant antibodies were cloned and expressed by Genscript. Briefly, selected 677 antibodies were codon-optimized for human expression. These DNA sequences were 678 synthesized and cloned into heavy and light chain pcDNA3.4 expression vectors. Heavy 679 chains were expressed as human IgG1 and light chains were expressed as either human 680 IGK or IGL as appropriate. Vectors were transiently transfected in HEK293-6E cells and 681 antibodies were purified from supernatant using Robocolumn Eshmuno A (EMD 682
Millipore) or Monofinity A Resin prepacked columns (Genscript). Purity generally >95% 683 384-well MaxiSorp plates (ThermoFisher) by overnight incubation at 4 C at 2 ng/uL 703 diluted in phosphate-buffered saline (PBS) pH 7.4, then three washes were performed. 704
When vaccine was used as antigen, vaccine was immobilized at a 50-fold dilution in PBS 705 pH 7.4. The plate was incubated for 2 hours at room temperature with blocking buffer 706 (PBS pH 7.4 with 0.05% Tween-20 and 2% bovine serum albumin [BSA]), then washed 707 twice. The plate was incubated with primary antibody diluted to 2 ng/uL unless otherwise 708 noted in blocking buffer for 2 hours at room temperature, then washed four times. The 709 plate was incubated with detection antibody (mouse anti-human IgG1 Fc conjugated to 710 horseradish peroxidase clone HP6069; ThermoFisher) for 2 hours at room temperature, 711 then washed five times. All washes consisted of 5 minute incubation with PBS pH 7.4 712 with 0.05% Tween-20. Detection was performed by adding 1-Step ABTS Substrate 713 (ThermoFisher), then measuring absorbance at 405 nm at 1 or 3 min intervals for 45 min. 714
Time point used for analysis was determined based on the dynamic range of the data 715 (increasing signal, but no saturation). Positive controls included the broadly binding anti-716 influenza antibodies MEDI8852 (24) and CR9114 (25) obtained as a gift from Dr. Peter 717
Kim. As negative controls, we used natural human IgG1 prepared from myeloma plasma 718 (Abcam), or incubated wells with PBS alone instead of antigen (referred to as "no 719
antigen") or blocking buffer alone instead of antibody (referred to as "no antibody"). 720 721
Binding measurements using biolayer interferometry 722
Kinetic measurements of antibody-antigen interactions were performed using biolayer 723 interferometry on a ForteBio Octet 96 instrument with anti-human IgG Fc capture (AHC) 724
biosensors. All assays were carried out in PBS with 1% BSA and 0.05% Tween-20 with a 725 total volume of 250 uL per well using the following protocol: 60 s baseline, 300 s loading 726 of antibody, 60 s baseline, 300 s association of antigen, and dissociation of variable 727 duration up to 600 s for high affinity interactions. Antibody was loaded at 1.5 ng/uL and 728 antigen concentrations ranged from 2.5 to 100 nM. Between assays, sensors were 729 regenerated by cycling between assay buffer and 10 mM glycine pH 1.5 for 30 s, then 730 quenched for 30 s in assay buffer. Data were processed using ForteBio software and 731
custom Python scripts to perform global fitting of a 1:1 binding model across 2-5 antigen 732 concentrations after double reference subtraction (using buffer only and analyte only 733 conditions). 734
To determine whether antibodies bind similar or overlapping epitopes, 735
competitive binding of antibody pairs to a specific antigen was characterized using anti-736 penta-HIS (HIS1K) biosensors. We used the following protocol: 60 s baseline, 300 s 737 loading of antigen, 60 s baseline, 900 s association of blocking antibody, 60 s baseline, 738
600 s association of test antibody. Antigen was HA H1N1 A/New Caledonia/20/1999 739 with an isoleucine zipper trimerization domain and polyhistidine tag obtained as a gift 740 from Dr. Peter Kim and used at 25 nM. Blocking antibodies were used at 400 nM and 741 included MEDI8852 (24), CR9114 (25), CH65 (26), H2897 (27), and 6649 (28) obtained 742
as gifts from Dr. Peter Kim. Test antibodies were used at 100 nM and included L3N1 and 743 L3N6. As a control, self-blocking assays were performed using the same antibody for 744
blocking and test steps, except with test antibody at 100 nM. Data were processed using 745
ForteBio software and custom Python scripts. We note that complete blocking was 746 observed between MEDI8852 and CR9114, which have overlapping epitopes. Partial 747
blocking was observed between 6649 and H2897, which have partially overlapping 748 epitopes. 749 750
Data and code availability 751
Sequence data, preprocessed data, and code will be made freely available at the time of 752 publication. IGHA1  IGHA2  IGHD  IGHE  IGHG1  IGHG2  IGHG3  IGHG4 CD19  MS4A1  CD27  CD79A  CD79B  BANK1  CD3E  IL32  IFITM1  IL7R  CD3D  CD7  HCST  GIMAP7  LCK  GNLY  NKG7  CST7  CD7  GZMA  LYZ  FOS  CST3  TYROBP  SRGN  NEAT1 Table S1 . Genes that are differentially expressed between naïve and memory B cells. 831 Differential expression between single-cell transcriptional profiles of naïve (n = 18,953) 832 and memory (n = 16,653) B cells was determined using the negative binomial exact test 833 with the Benjamini-Hochberg correction for multiple testing. Genes with P < 0.05 are 834
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shown. Genes upregulated in memory B cells are shown first, then genes upregulated in 835 naïve B cells. 836 837 Table S2 . Genes that are differentially expressed between memory and activated 838 memory B cells. 839
Differential expression between single-cell transcriptional profiles of memory (n = 840 16,653) and activated memory (n = 421) B cells was determined using the negative 841 binomial exact test with the Benjamini-Hochberg correction for multiple testing. Genes 842 with P < 0.05 are shown. Genes upregulated in activated memory B cells are shown first, 843 then genes upregulated in memory B cells. 844 845
